Evidence map›Paper›PMID 26045865›Full record

ArticleInternational journal of clinical and experimental pathology2015

Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer.

Jing Zhao, Jianya Zhou, Zhen Chen, Bo Wang, Xiuming Zhang, Jianying Zhou, Wei Ding

Open access · greenAbstract readCase Reports
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jing ZhaoDepartment of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou, China.
Jianya ZhouDepartment of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou, China.
Zhen ChenDepartment of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou, China.
Bo WangDepartment of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou, China.
Xiuming ZhangDepartment of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou, China.
Jianying ZhouDepartment of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou, China.
Wei DingDepartment of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou, China.
Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

EML4-ALK rearrangement is detected in 2% to 7% of lung adenocarcinomas, these tumors are sensitive to crizotinib. The histologic feature of ALK translocated non-small-cell lung cancer (NSCLC) has been studied, presence of signet-ring cells was a powerful histologic indicator of ALK rearrangement, and this characteristic histology was present both in primary sites and metastases. However, the case we discribed here has different histomorphology in primary sites and metastases, but has the same genotype which both present ALK rearrangement, while absent of EGFR mutation, KRAS mutation and ROS1 rearrangement. This histologic heterogeneity may be a supplement of the histologic feature of ALK rearranged tumor. Moreover, genomic analysis can help distinguish clonal tumors from independent primaries.

Indexed as

Gene RearrangementAdenocarcinomaAdenocarcinoma of LungAdultAnaplastic Lymphoma KinaseBiomarkers, TumorBiopsyCarcinoma, Non-Small-Cell LungDNA Mutational AnalysisErbB ReceptorsGenetic Predisposition to DiseaseHumansImmunohistochemistryIn Situ Hybridization, FluorescenceLung NeoplasmsMaleALK protein, humanAnaplastic Lymphoma KinaseBiomarkers, TumorEGFR protein, humanErbB ReceptorsKRAS protein, humanProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Receptor Protein-Tyrosine KinasesROS1 protein, humanALK rearrangementhistologyLung adenocarcinomametastasis

Identifiers

PMID26045865
PMCPMC4440174
OpenAlexW2406677316

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.